
Vir Biotechnology, Inc. – NASDAQ:VIR
Vir Biotechnology stock price today
Vir Biotechnology stock price monthly change
Vir Biotechnology stock price quarterly change
Vir Biotechnology stock price yearly change
Vir Biotechnology key metrics
Market Cap | 1.02B |
Enterprise value | 2.39B |
P/E | 5.98 |
EV/Sales | 1.48 |
EV/EBITDA | 3.10 |
Price/Sales | 1.92 |
Price/Book | 1.50 |
PEG ratio | -0.48 |
EPS | -4.01 |
Revenue | 56.34M |
EBITDA | -554.72M |
Income | -539.43M |
Revenue Q/Q | 20.68% |
Revenue Y/Y | -85.81% |
Profit margin | 31.92% |
Oper. margin | 51.56% |
Gross margin | 90.94% |
EBIT margin | 51.56% |
EBITDA margin | -984.55% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVir Biotechnology stock price history
Vir Biotechnology stock forecast
Vir Biotechnology financial statements
Jun 2023 | -12.72M | -194.77M | 1531.01% |
---|---|---|---|
Sep 2023 | -4.09M | -163.41M | 3987.63% |
Dec 2023 | 16.78M | -115.97M | -690.85% |
Mar 2024 | 56.37M | -65.27M | -115.79% |
Mar 2024 | 56.37M | -65.27M | -115.79% |
---|---|---|---|
Sep 2025 | 18.4M | -150.76M | -819.36% |
Oct 2025 | 18.4M | -129.86M | -705.81% |
Dec 2025 | 18.4M | -78.46M | -426.43% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 2243874000 | 433.66M | 19.33% |
---|---|---|---|
Sep 2023 | 2044895000 | 369.81M | 18.08% |
Dec 2023 | 1960090000 | 369.85M | 18.87% |
Mar 2024 | 1793969000 | 246.61M | 13.75% |
Jun 2023 | -389.24M | 230.31M | 3.17M |
---|---|---|---|
Sep 2023 | -155.82M | -58.95M | 277K |
Dec 2023 | -107.92M | -104.81M | 1.68M |
Mar 2024 | -109.39M | 28.42M | 152K |
Vir Biotechnology alternative data
Aug 2023 | 576 |
---|---|
Sep 2023 | 576 |
Oct 2023 | 576 |
Nov 2023 | 576 |
Dec 2023 | 576 |
Jan 2024 | 576 |
Feb 2024 | 576 |
Mar 2024 | 587 |
Apr 2024 | 587 |
May 2024 | 587 |
Jun 2024 | 587 |
Jul 2024 | 587 |
Vir Biotechnology other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 85685 |
Mar 2024 | 0 | 6008 |
Apr 2024 | 0 | 75706 |
Jun 2024 | 0 | 4000 |
Sep 2024 | 0 | 12190 |
Nov 2024 | 0 | 8147 |
Dec 2024 | 0 | 76 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | DE VERNEUIL VANINA officer: EVP and General Counsel | Common Stock | 76 | $8.22 | $625 | ||
Sale | DE VERNEUIL VANINA officer: EVP and General Counsel | Common Stock | 4,397 | $10.11 | $44,454 | ||
Sale | DE VERNEUIL VANINA officer: EVP and General Counsel | Common Stock | 2,347 | $9.47 | $22,226 | ||
Sale | DE VERNEUIL VANINA officer: EVP and General Counsel | Common Stock | 1,403 | $7.2 | $10,107 | ||
Sale | NAPOLITANO JANET director | Common Stock | 12,190 | $7.8 | $95,033 | ||
Sale | RAMASASTRY SAIRA director | Common Stock | 4,000 | $10.95 | $43,788 | ||
Sale | DE BACKER MARIANNE director, officer: Chief Execut.. | Common Stock | 72,995 | $9.46 | $690,387 | ||
Sale | HANLY ANN M. officer: EVP & Chief Technology.. | Common Stock | 2,711 | $10.05 | $27,251 | ||
Sale | LEE SUNG officer: EVP & Chief Financial .. | Common Stock | 6,008 | $9.89 | $59,407 | ||
Sale | SCANGOS GEORGE A director | Common Stock | 17,722 | $11.65 | $206,514 |
Patent |
---|
Application Filling date: 10 Nov 2021 Issue date: 28 Apr 2022 |
Application Filling date: 19 Dec 2019 Issue date: 24 Feb 2022 |
Application Filling date: 20 Sep 2019 Issue date: 3 Feb 2022 |
Application Filling date: 23 Jul 2021 Issue date: 2 Dec 2021 |
Grant Filling date: 25 Feb 2021 Issue date: 9 Nov 2021 |
Application Filling date: 25 Feb 2021 Issue date: 26 Aug 2021 |
Application Filling date: 31 Aug 2020 Issue date: 18 Feb 2021 |
Application Filling date: 31 Aug 2020 Issue date: 18 Feb 2021 |
Grant Filling date: 5 Oct 2015 Issue date: 19 Jan 2021 |
Quarter | Transcript |
---|---|
Q1 2024 3 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Fulgent Genetics: Growth Is Returning
Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments
Vir Biotechnology: A Beaten Up Biotech With A Large Margin Of Safety
Intellia Therapeutics: The Future Is Here
Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023
-
What's the price of Vir Biotechnology stock today?
One share of Vir Biotechnology stock can currently be purchased for approximately $4.35.
-
When is Vir Biotechnology's next earnings date?
Unfortunately, Vir Biotechnology's (VIR) next earnings date is currently unknown.
-
Does Vir Biotechnology pay dividends?
No, Vir Biotechnology does not pay dividends.
-
How much money does Vir Biotechnology make?
Vir Biotechnology has a market capitalization of 1.02B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 94.55% to 86.18M US dollars.
-
What is Vir Biotechnology's stock symbol?
Vir Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "VIR".
-
What is Vir Biotechnology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vir Biotechnology?
Shares of Vir Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vir Biotechnology's key executives?
Vir Biotechnology's management team includes the following people:
- Dr. Herbert W. Virgin IV Executive Vice President of Research & Chief Scientific Officer(age: 69, pay: $1,110,000)
- Dr. George A. Scangos Pres, Chief Executive Officer & Director(age: 77, pay: $994,880)
- Mr. Steven J. Rice Chief Admin. Officer(age: 65, pay: $698,620)
- Mr. Howard Horn Chief Financial Officer & Sec.(age: 47, pay: $681,830)
-
How many employees does Vir Biotechnology have?
As Jul 2024, Vir Biotechnology employs 587 workers.
-
When Vir Biotechnology went public?
Vir Biotechnology, Inc. is publicly traded company for more then 5 years since IPO on 11 Oct 2019.
-
What is Vir Biotechnology's official website?
The official website for Vir Biotechnology is vir.bio.
-
Where are Vir Biotechnology's headquarters?
Vir Biotechnology is headquartered at 499 Illinois Street, San Francisco, CA.
-
How can i contact Vir Biotechnology?
Vir Biotechnology's mailing address is 499 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59064324.
Vir Biotechnology company profile:

Vir Biotechnology, Inc.
vir.bioNASDAQ
587
Biotechnology
Healthcare
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
San Francisco, CA 94158
CIK: 0001706431
ISIN: US92764N1028
CUSIP: 92764N102